Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | PRKACA | P17612 | 1/20 | 0.39 |
| ▸ | PRKACG | P22612 | 1/20 | 0.39 |
| ▸ | PRKACB | P22694 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2002531 | 0.90 | PTGS2 (0.52) | PTGS2PTGS1AKR1C3AKR1C2GAA | |
| SCHEMBL6424914 | 0.90 | PTGS2 (0.47) | PTGS2PTGS1SRCPRKACAPRKACG | |
| SCHEMBL5545939 | 0.88 | PTGS2 (0.65) | PTGS2PTGS1AKR1C3AKR1C2LMNA | |
| SCHEMBL2005310 | 0.88 | PTGS2 (0.50) | PTGS2PTGS1AKR1C3AKR1C2 | |
| SCHEMBL5549754 | 0.88 | PTGS2 (0.65) | PTGS2PTGS1AKR1C3AKR1C2LMNA | |
| SCHEMBL5545907 | 0.88 | PTGS2 (0.65) | PTGS2PTGS1AKR1C3AKR1C2LMNA | |
| SCHEMBL6424459 | 0.86 | PTGS2 (0.47) | PTGS2PTGS1SRCPRKACAPRKACG | |
| SCHEMBL6424769 | 0.86 | PTGS2 (0.49) | PTGS2PTGS1SRCPRKACAPRKACG | |
| SCHEMBL6423155 | 0.86 | PTGS2 (0.47) | PTGS2PTGS1AKR1C3AKR1C2 | |
| SCHEMBL6423159 | 0.86 | PTGS2 (0.47) | PTGS2PTGS1AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | IRONWOOD PHARMACEUTICALS, INC. | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | FAAH2, FAAH, PTGES2 | PTGS2 4/4885PTGS1 7/4885SRC 3467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.